Biopharma Money on the Move: December 16-22 – BioSpace
Posted: December 26, 2020 at 2:57 pm
Last call for raising funds beforeChristmas, andthese companies didnt hesitate to scoop up their bags of cash.
TG Therapeutics
TG has been on the Nasdaq for over sevenyears now, but 2020 has been theyear for the New Yorkbiopharmato soar.With shares trading atless than $11 apiece in January, the stock is now well over $50 since theannouncementof positive topline results from two global Phase III trials for relapsing forms of MS.With a high probability of FDA approval, TG cashed inwith an upsized common stock offering,raising$300 millionto further develop and commercializetheir therapies.
BioAtla
This San Diego company hopped on the bandwagon of biopharma IPOs last week, offering 10.5M million shares at $18 apiece, a 38% increase, scooping up$189 millionin proceeds.BioAtlais developing a novel class of specific and selective antibody-based therapeutics.The companys conditionally active biologics only activate when they detect proximity to a tumor, thereby reducingsystemictoxicity.Funds will propel the companys two lead programs through three Phase II trials.
Cullinan Oncology
Breaking down the silos of drug research, Cullinan applies open innovation and collaboration to developa portfolio of first-in-class and best-in-classcancer therapies. With an oversubscribed$131.2 millionSeries C, the Cambridge company can advanceitsseven-candidatepipelineinto the clinic.Each candidate isstructured as a separate company managed by Cullinan. Two are currently in Phase I with an inhibitor drug for NSCLC and amonoclonal antibody reinvigorating the MICA/NKG2D axis.
Neurogene
New York-basedNeurogeneis establishing itself as a leader in gene therapies for neurological diseases. Last weeks$115 millionSeries B round willhelp advance multiple of the companys candidates into the clinic. The first of which targetslate infantileBattens Disease,a rare nervous system disorder that worsens over time and is fatal, usually 8-10 years old.The funds will also be used to build outNeurogenesadeno-associated virus vector GMP manufacturing capabilities.
Neuron23
Having worked undercover for two years, Neuron23 uncloakedlast weekwith$113.5 millionin financing for its launch.$30 million of the funds came from Westlake Village BioPartners, who just announcedtwo funds totaling$500 millionwith the intent to invest in Series A startups in the most promising companies.Neuron23 has hit the ground running, aiming to take on Parkinsons diseaseagainst giant Biogen, who recentlyorchestratedin a $1 billion dealwith Denaliwith the same target in mind. The plan is to start trials with healthy volunteers next year.
Neomorph
Established earlier this year, San Diego-based Neomorph raked in$109 millionin a Series A. The companys focus is on targeted proteindegradation, which offers opportunities for treatment developments across the board, including oncology.The Neomorph team has deep expertise in pharmacological approaches to targeted protein degradation and we are excited to be developing new therapeutics for patients with diseases that are currently difficult to treat, said scientific founderScottArmstrongMD, Professor of Pediatrics at Harvard Medical School and the Dana-Farber Cancer Institute.
AtsenaTherapeutics
Gene therapy startupAtsenaclosed on an oversubscribed$55 millionSeries A.The funds will be used to advance itsgene therapy for one of the most common cause of blindness in children through clinical trials.Leber congenital amaurosis (LCA) causes blindness in 2 to 3 out of 100,000 newborns.The company isalso planning for growth,looking to move into a larger space next yearto scale up gene therapy manufacturing. Ramping up across the board, theres a goal to hire 20 more positions with the move.
ONL Therapeutics
With support from Johnson & Johnson and more, Michigan-based ONL closed a$46.9 millionSeries B Preferred Stock financing round.The company is developing therapies for protecting the patients with retinal disease from vision loss.This funding supports the completion of a Phase 1 study in retinal detachment with ONLs lead compound ONL1204. In addition, the funding will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration.
Peptilogics
Peptilogicsis the most recent biotech receiving investments fromPaypalsco-founder Peter Thiel. This week, Thiel participated in a$35 millionfinancing round for the Pennsylvania-basedcompany.The funds will be used to advancePeptilogicsproprietarycomputational peptide drug design and discovery platform. The platform discovers connections in diverse biomedical data and maps peptide sequences.
Octave Bioscience
Looking totakeitsfully integratedcare management platform to the next level, Octave completed a$32 millionSeries B financing round. The funds will allow thecompany to complete development of management products and services, expand clinical data and begin commercialization to neurologists and patients. Octaves first target has been multiple sclerosis patients, but will expand to other chronic, debilitating neurodegenerative diseases. Theplatformtracksblood-basedbiomarkers, enhanced MRI insights and mobile patient monitoring tools to feed intocare pathwaymodels to generatebetter patient outcomes and lower costs.
Vivace Therapeutics
Small molecule player Vivace closed a$30 millionSeries C for further development of its first-in-class therapies targeting the Hippo pathway. Funds will be usedto take its lead candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP.Pre-clinical research has shown promise for the candidate both as a monotherapy and in combination with other anti-cancer therapies.
Most Read Today
Original post:
Biopharma Money on the Move: December 16-22 - BioSpace
- First-in-Human Clinical Trial to Assess Gene Therapy for Alzheimer's Disease - UC San Diego Health - February 19th, 2021
- Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR in Gene Therapy - PRNewswire - February 19th, 2021
- UC San Diego: First-in-Human Clinical Trial to Assess Gene Therapy for Alzheimers Disease - India Education Diary - February 19th, 2021
- Charles River acquires Cognate BioServices to expand cell and gene therapy programs - BioPharma-Reporter.com - February 19th, 2021
- Duchenne UK and Parent Project Muscular Dystrophy Award $350,000 to Address Immunological Challenges of Gene Therapy in Duchenne Muscular Dystrophy -... - February 19th, 2021
- Global Gene Therapy Market Outlook to 2030 - by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of... - February 19th, 2021
- Sensorion and Institut Pasteur announce new gene therapy collaboration - BioPharma-Reporter.com - February 19th, 2021
- Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development - Business Wire - February 19th, 2021
- Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and... - February 19th, 2021
- Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition - BioSpace - February 19th, 2021
- Most Elevated Read 2020 on Cancer Gene Therapy Market To Witness Robust Expansion Throughout The Forecast Period 2026 KSU | The Sentinel Newspaper -... - February 19th, 2021
- Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease -... - February 19th, 2021
- Global Genome Editing Market Is Expected to Reach USD 17.36 Billion by 2028 : Fior Markets - GlobeNewswire - February 19th, 2021
- REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD - BioSpace - February 19th, 2021
- IO Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment... - February 19th, 2021
- The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 20212026 - GlobeNewswire - February 17th, 2021
- Global Gene Therapy Market Industry Trends and Forecasts 2020-2030: Big Pharma Players and Analysis of Gene Therapy Related Initiatives -... - February 17th, 2021
- Global Gene Therapy Products Market Study including Growth Factors, New Top Players, Competitive Analysis by regions from 2021 to 2027 - The Courier - February 17th, 2021
- REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD - The Baytown Sun - February 17th, 2021
- Forge Biologics Receives FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for FBX-101 Gene Therapy for Patients with Krabbe... - February 17th, 2021
- Europe Cell and Gene Therapy Market Industry Outlook and Forecast Report 2021-2026 with Data-driven Insights on the Impact of COVID-19 -... - February 17th, 2021
- Dyno Therapeutics Announces Publication in Nature Biotechnology Demonstrating Use of Artificial Intelligence to Generate Unprecedented Diversity of... - February 17th, 2021
- Global Cancer Gene Therapy Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel... - February 17th, 2021
- Rentschler Biopharma to build new cell and gene therapy capabilities in the UK - BioSpace - February 17th, 2021
- Aldevron expands manufacturing capabilities in Madison - University of Wisconsin-Madison - February 17th, 2021
- Rare Disease Gene Therapy Market: Increasing cases of genetic diseases to drive the market - PharmiWeb.com - February 17th, 2021
- Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments - BioSpace - February 17th, 2021
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome - GlobeNewswire - February 17th, 2021
- News > Science > Visualisation of 'dancing DNA' - University of Leeds - February 17th, 2021
- New study suggests genetic testing could be appropriate for all motor neuron disease (MND) patients whether or not they have a family history of the... - February 17th, 2021
- Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005 - Business Wire - February 17th, 2021
- Hemophilia A Market Domain to Witness Growth at a CAGR of 10.2% over the Study Period 2018-30 in the 7MM, Estimates DelveInsight - PRNewswire - February 17th, 2021
- Global Cancer Gene Therapy Market Is Projected to Grow at an Exponential Rate over 2020 to 2028 | Market Top Players Analysis, Revenue, Application,... - February 17th, 2021
- North America Virus Filtration Market 2020-2026: Surging Need for Virus Removal and Clearance amid COVID-19 Pandemic - PRNewswire - February 17th, 2021
- Janssen R&D puts itself into a strong position in ophthalmology through research collaboration with Verana Health - pharmaceutical-technology.com - February 17th, 2021
- CAR-T Cell Therapy Receives FDA Approval to Treat Certain Types of Large B-Cell Lymphoma - Curetoday.com - February 7th, 2021
- Liso-cel Receives FDA Approval for the Treatment of R/R Large B-Cell Lymphoma - Cancer Network - February 7th, 2021
- Europe Cell and Gene Therapy Market Size to Reach Revenues of USD 2.9 Billion by 2026 - Arizton - PRNewswire - February 7th, 2021
- The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight - Yahoo Finance - February 7th, 2021
- Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key... - February 6th, 2021
- Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - BioSpace - February 6th, 2021
- Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)... - February 6th, 2021
- Regenerative Medicine Market to be Valued at USD 6.49 Billion by 2027 | The Escalating Burden of Chronic Diseases and Genetic Aberrations will be the... - February 6th, 2021
- FDA Issues More Guidance on Gene and Cell Therapy Products - JD Supra - February 6th, 2021
- Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics - BioSpace - February 6th, 2021
- Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy - BioSpace - February 6th, 2021
- Aruvant Announces the European Medicines Agency (EMA) Granted Priority Medicines (PRIME) Designation to ARU-1801 for the Treatment of Sickle Cell... - February 6th, 2021
- Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult - PharmiWeb.com - February 6th, 2021
- The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis -... - February 6th, 2021
- Retinal Gene Therapy Market: Advent of High-end Technologies to Support Development of the Market - BioSpace - February 6th, 2021
- Angiocrine Bioscience Announces Oral Presentation of Intravenous AB-205 Data during the Annual Transplantation & Cellular Therapy Meetings of ASCT... - February 6th, 2021
- M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board - BioSpace - February 6th, 2021
- University of Sheffield receives record donation to support disadvantaged students and pioneering medical research - University of Sheffield News - February 6th, 2021
- Sanofi Succeeding with Blue-Chip Asset, Dupixent, While Other Programs Fall Away - BioSpace - February 6th, 2021
- Craig Lockhart named chief of hematology and oncology at MUSC - The Cancer Letter - January 31st, 2021
- Are Gene Therapies the Medicine of the Future? - BioSpace - January 29th, 2021
- Researchers use patients' cells to test gene therapy for rare eye disease - National Institutes of Health - January 29th, 2021
- Gene Therapy Market to Reach US$ 20.9 Billion by 2027, Globally |CAGR: 29.7%|UnivDatos Market Insights - PR Newswire India - January 29th, 2021
- First hybrid gene therapy shows early promise in treating long QT syndrome - Newswise - January 29th, 2021
- Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing - Labiotech.eu - January 29th, 2021
- Cell and Gene Therapy Market Size to Reach USD 7,250.0 Million by 2028 | Increasing Investments in Production Capacity Expansion for Cell and Gene... - January 29th, 2021
- Provention Bio Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy -... - January 29th, 2021
- One-dose COVID-19 vaccine candidate that can be stored at room temperature prompts immunity in animals - FierceBiotech - January 29th, 2021
- Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer - PRNewswire - January 29th, 2021
- Nanobiotix Subsidiary Curadigm Secures New Collaboration Agreement With Sanofi Focused on Gene Therapy Pipeline - Business Wire - January 29th, 2021
- Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Expected to Grow at a Significant CAGR of 43.4% During the Study Period 2019-30 -... - January 29th, 2021
- Gene editing: beyond the hype - - pharmaphorum - January 29th, 2021
- Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership - GlobeNewswire - January 29th, 2021
- Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results - BioSpace - January 29th, 2021
- Protein identified that may help treat Parkinsons disease - Medical News Today - January 29th, 2021
- Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief... - January 29th, 2021
- Decibel Therapeutics and Invitae Announce Launch of Amplify Genetic Testing Program - BioSpace - January 29th, 2021
- Ambulero Raises Up To $5.5 Million from Orphinic ScientificMiami Cell and Gene Therapy Company Opens European Subsidiary To Advance Gene Therapy For... - January 29th, 2021
- ARK's Big Ideas for 2021 lists the firm's 'most provocative research conclusions for the year' - ETF Express - January 29th, 2021
- Advarra Announces New Gene Therapy Ready Site Network - PRNewswire - January 23rd, 2021
- UK biotech Ixaka scores additional funding for cell and gene therapy research - PharmaTimes - January 23rd, 2021
- Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies - Business Wire - January 23rd, 2021
- Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy - BioSpace - January 23rd, 2021
- Cancer Gene Therapy Market Size Study with COVID-19 Impact 2020, Share, Industry Analysis, Growth, Segmentation and Forecast to 2026 KSU | The... - January 23rd, 2021
- Chinese scientists develop new gene therapy that can delay the aging process - National Post - January 23rd, 2021